Talphera Welcomes Joe Todisco to Its Board of Directors with Strategic Vision

Talphera Expands Leadership with Appointment of Joe Todisco

Talphera, Inc., a notable specialty pharmaceutical company listed on Nasdaq (TLPH), has recently made a significant move to strengthen its Board of Directors. The company is focused on the development and commercialization of innovative therapies, particularly for medically supervised settings. As of October 21, 2025, Joe Todisco, who is currently the CEO of CorMedix Inc., has been appointed to the board, marking a strategic milestone for Talphera.

This appointment is particularly noteworthy as it follows a recent strategic investment by CorMedix, aimed at enhancing the growth trajectory of Talphera. In September of this year, CorMedix made a substantial financial commitment to Talphera as part of a private placement financing. In conjunction with this investment, CorMedix secured the right to nominate a representative to Talphera’s board, which now includes Todisco.

Adrian Adams, the Chairman of Talphera's Board, expressed enthusiasm about the addition of Mr. Todisco to the team, highlighting his extensive background in the pharmaceutical industry. "Joe has demonstrated exceptional leadership within CorMedix during a pivotal time of growth and expansion," Adams stated. He is optimistic about the synergistic potential Todisco brings to Talphera, particularly as they look to maximize the prospects of their lead product candidate, Niyad.

In a statement, Todisco shared his eagerness to collaboratively work with the Talphera team on their endeavors. He highlighted the potential of Niyad, which is being developed with the aim of becoming a new standard of care for anticoagulation in Continuous Renal Replacement Therapy (CRRT). This reflects a growing emphasis on targeted therapies that meet the needs of patients in critical care settings.

Overview of Niyad and Its Significance

Niyad is a unique formulation of nafamostat, a multi-functional synthetic serine protease inhibitor known for its anticoagulant, anti-inflammatory, and potential anti-viral properties. This innovative product is currently being studies under an Investigational Device Exemption (IDE) as an anticoagulant intended for use in extracorporeal circuits during CRRT procedures. In recognition of its promise, the U.S. Food and Drug Administration (FDA) has granted Niyad Breakthrough Device Designation, signaling its potential impact on patient care.

The pivotal clinical study for Niyad, known as the NEPHRO CRRT trial, is designed to enroll approximately 70 adult patients who are undergoing renal replacement therapy but are unable to tolerate heparin or are at risk of bleeding. The trial aims to establish the efficacy of Niyad by measuring various clinical endpoints, including activated clotting times and filter lifespan.

Future Implications

The strategic investment by CorMedix and the subsequent appointment of Todisco not only enhance Talphera’s governance but also align with their long-term vision of providing cutting-edge therapies that ensure optimal patient outcomes. The collaboration embodies a proactive approach toward expanding Talphera’s portfolio and driving forward the clinical development of Niyad.

In closing, as Talphera looks ahead to potential FDA approval of Niyad in 2026, the addition of Joe Todisco seems poised to play a critical role in shaping the company's direction and maximizing its contributions to the pharmaceutical landscape. With a well-defined strategy and robust leadership, Talphera is positioning itself as a frontrunner in innovative therapeutics and patient-centered care.